VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx (VNRX) presented early-stage cancer detection data at ESMO MAP, showing 95% detection of stage I/II cancers using its Capture-Seq™ technology. The company targets a $36B market in early cancer detection and MRD, with plans to accelerate development and patent protection. Results showed no false positives in initial cohorts, with further studies underway.

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

Autoliv, Inc. reported Q3 2026 earnings, outperforming global light vehicle production by 1%, with strong growth in China and India. The company reiterated flat full-year sales guidance and narrowed adjusted operating margin to ~10.5%. Challenges include raw material and logistics headwinds, but management expects Q4 margin expansion. Autoliv also lowered capital expenditure guidance and noted a slight increase in leverage ratio.

Dr. Reddy's Laboratories (RDY) reported Q2 2027 earnings with revenue down 8.8% to $903.9M, operating profit down 71.6% to $132.2M, and net income down 40.4% to $96.4M. Cash from operations fell 67.4% to $55.2M. The stock dropped 2.69% in morning trading. Institutional investors showed mixed activity, with some adding and others reducing their positions.

SL Green reported Q3 funds from operations of $122.1M, up from Q2 and the prior year, driven by sales of two Manhattan properties. Net income rose to $72.2M. Leasing activity slowed in deal count but increased in square footage. Revenue reached $273M, up from previous periods. The company hedged against interest rate increases, mitigating some impact.